Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Response to: “Commentary on: phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s disease: a retrospective cohort study”

International Journal of Impotence Research volume 36, pages 297–298 (2024)Cite this article

Subjects

We appreciate the commentary by Manfredi et al. on our study investigating the impact of phosphodiesterase type 5 inhibitors (PDE5is) on Peyronie’s disease (PD) in the active phase [1]. The attention devoted to non-surgical interventions in PD in recent years highlights a growing recognition of the need for effective non-invasive treatments for this condition. This increased focus may reflect a broader shift in medical practice towards holistic patient care, emphasizing options beyond surgical intervention. Despite the paucity of clinical studies, PDE5is hold promise as a viable, safe, and practical approach to managing the condition, potentially offering relief and influencing its progression [2, 3]. With their generally well-tolerated nature and favorable safety profile [4], PDE5is emerge as an appealing choice for PD management.

In our retrospective cohort study, 133 patients with PD in the active phase were included. Group 1 (n = 101) received continuous treatment with PDE5is, while Group 2 (n = 32) received no treatment. The curvature progression was recorded over a mean follow-up of approximately one year. Between the first and last observations, Group 1 exhibited a mean penile curvature change of + 0.87° (95% CI: −1.8, 3.5), whereas Group 2 experienced a larger increase of + 5.72° (95% CI: 1.4, 10). Although there was a numerical difference in curvature progression, it did not reach statistical significance (p = 0.07), and the variance was small compared to what would be considered clinically meaningful [5]. Meanwhile, Group 1 exhibited a shorter mean duration of pain of 9.1 months (SD 4.7), compared to Group 2 reporting a mean pain duration of 12.2 months (SD 6.5) (p = 0.04).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Manfredi C, Bologna E, Licari LC. Commentary on “Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s disease: a retrospective cohort study”. Int J Impot Res. 2023;1–2. https://doi.org/10.1038/s41443-023-00811-4.

  2. Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med. 2011;8:1472–7.

    Article  CAS  PubMed  Google Scholar 

  3. Spirito L, Manfredi C, La Rocca R, Napolitano L, Di Girolamo A, Capece M, et al. Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie’s disease: a retrospective comparative analysis. Int J Impot Res. 2022. https://doi.org/10.1038/S41443-022-00651-8.

  4. Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. Pharm Ther. 2013;38:407.

    Google Scholar 

  5. Durukan E, Kraglund R, Rashid SA, Thorkilgaard T, Jensen CFS, Fode M. Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s Disease: a retrospective cohort study. Int J Impot Res. 2024: 1–4. https://doi.org/10.1038/s41443-023-00810-5.

  6. Joseph J, Ziegelmann MJ, Alom M, Savage J, Köhler TS, Trost L. Outcomes of RestoreX penile traction therapy in men with Peyronie’s disease: results from open label and follow-up phases. J Sex Med. 2020;17:2462–71.

    Article  PubMed  Google Scholar 

  7. Raheem AA, Garaffa G, Raheem TA, Dixon M, Kayes A, Christopher N, et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie’s disease. BJU Int. 2010;106:1178–1180.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark

    Emil Durukan, Christian Fuglesang Skjødt Jensen & Mikkel Fode

  2. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

    Emil Durukan & Mikkel Fode

Authors
  1. Emil Durukan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Fuglesang Skjødt Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mikkel Fode
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ED: Manuscript writing and editing, CFSJ: Manuscript reviewing and editing, MF: Manuscript reviewing, editing and supervision.

Corresponding author

Correspondence to Emil Durukan.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Durukan, E., Jensen, C.F.S. & Fode, M. Response to: “Commentary on: phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s disease: a retrospective cohort study”. Int J Impot Res 36, 297–298 (2024). https://doi.org/10.1038/s41443-024-00872-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41443-024-00872-z

Search

Advanced search

Quick links